On October 27, 2023 Specialty reported care growth, strong launch uptake of Beyfortus and ALTUVIIIO drive solid Q3 results (Press release, Sanofi, OCT 27, 2023, View Source [SID1234638477]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q3 2023 sales growth of 3.2% at CER and business EPS(1) decrease of 2.1% at CER
• Specialty Care grew 13.5% driven by Dupixent (€2,847 million, +32.8%) and ALTUVIIIO more than offsetting
the impact of Aubagio generic competition in the U.S.
• Stable Vaccines sales (-0.6%) benefited from strong Beyfortus launch offsetting lower influenza vaccines sales
• General Medicines core assets grew 3.1%, non-core assets declined mainly due to Lantus (€343 million, –
32.9%)
• CHC sales grew 4.6% driven by Digestive Wellness and Allergy categories
• Business EPS(1) of €2.55, down 11.5% on a reported basis and down 2.1% at CER with Aubagio LOE
• IFRS EPS of €2.01 (up 21.1%)
Key R&D milestones and regulatory achievements in Q3
• Beyfortus U.S. approval for prevention of RSV lower respiratory tract disease in infants
• ALTUVIIIO approval for hemophilia A in Japan and Nexviazyme for the treatment of Pompe disease in China
Progress on Corporate Social Responsibility strategy in Q3
• Sanofi Global Health Unit: first deliveries of cardio-metabolic products under the Impact brand to the Republic of
Djibouti and to global non-governmental organizations
Full-year 2023 business EPS guidance reiterated
• Sanofi expects 2023 business EPS(1) to grow mid single-digit(2) at CER, barring unforeseen major adverse events.
Applying average October 2023 exchange rates, the currency impact on 2023 business EPS is estimated between
-6.0% to -7.0%. This guidance includes approximately €400 million of expected one-off COVID vaccine revenues
in the fourth quarter.
Paul Hudson, Sanofi Chief Executive Officer, commented:
"The continued impressive performance of Dupixent, the highly anticipated launch of Beyfortus for the protection
of all infants against RSV and the strong uptake of ALTUVIIIO in hemophilia were key drivers in the quarter,
exemplifying our successful strategy execution towards sustainable growth from innovative medicines. The underlying
strength of our growth drivers more than offset the expected impact from generic competition on Aubagio in U.S.
and lower sales from mature products across the General Medicines portfolio in the quarter. With our two recent
business development deals in immunology and vaccines, we are further strengthening the core of our innovative
pipeline and follow our strategic focus of transforming the practice of medicine through breakthrough science. As we
enter a compelling next chapter of our company’s Play to Win strategy, we remain confident in the outlook for the
last quarter and consequently keep our full-year earnings guidance unchanged."
Q3 2023 Change Change
at CER
9M 2023 Change Change
at CER
IFRS net sales reported €11,964m -4.1% +3.2% €32,151m -0.4% +3.9%
IFRS net income reported €2,525m +21.6% _ €5,955m +13.2% —
IFRS EPS reported €2.01 +21.1% _ €4.76 +13.3% —
Free cash flow(3) €1,853m -31.2% _ €4,982m -16.1% —
Business operating income €4,028m -10.4% -1.0% €10,087m -2.2% +4.1%
Business net income(1) €3,196m -11.4% -1.9% €8,072m -1.6% +4.8%
Business EPS(1) €2.55 -11.5% -2.1% €6.45 -1.5% +4.9%
Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 7). (1) In order to facilitate an
understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-IFRS financial
measure (definition in Appendix 7). The consolidated income statement for Q3 2023 is provided in Appendix 3 and a reconciliation of reported IFRS net
income to business net income is set forth in Appendix 4; (2) 2022 business EPS was €8.26; (3) Free cash flow is a non-IFRS financial measure
(definition in Appendix 7).